Acusphere raises $20M from Cephalon


Watertown, MA-based biotech firm Acusphere (NASDAQ:ACUS) reports it has received a $5 million initial fee and $15 million in loans from biotech company Cephalon (NASDAQ:CEPH), headquartered in Frazer, PA. The deal gives Cephalon an exclusive worldwide license to Acusphere’s injectable formulation of anti-inflammatory drug celecoxib, which is in preclinical development.

By posting a comment, you agree to our terms and conditions.